Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials
- 18 August 2023
- journal article
- review article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (16) , 15293-15310
Abstract
The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway regulates proliferation, survival and metabolism, and its dysregulation is one of the most frequent oncogenic events across human malignancies. Over the last two decades, there has been significant focus on the clinical development of PI3K pathway inhibitors. More than 40 different inhibitors of this axis have reached various stages of clinical trials, but only a few of them have been approved by the Food and Drug Administration (FDA) for cancer treatment. These clinical results, however, could be improved given the importance of PI3K signaling in cancer and its role in linking cancer growth with metabolism. In this systematic review, after a glance at PI3K/AKT/mTOR pathway and its different inhibitors, we retrieved registered clinical trials evaluating the efficacy and safety of PI3K/AKT/mTOR inhibitors on Clinicaltrials.gov. Following the extraction of the data, finally we analyzed 2250 included studies in multiple steps, beginning with an overview and moving on to the details about type of malignancies, inhibitors, and treatment strategies. We also took a closer look at more than 100 phase III-IV clinical trials to pinpoint promising therapies, hoping that presenting a comprehensive picture of current clinical trials casts a flash of light on what remains to be done in future clinical trials of PI3K/AKT/mTOR inhibitors in human malignancies.Keywords
This publication has 34 references indexed in Scilit:
- Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway InhibitorsMolecular Cancer Therapeutics, 2014
- Targeting the PI3-Kinase/Akt/mTOR Signaling PathwaySurgical Oncology Clinics of North America, 2013
- Challenges in the clinical development of PI3K inhibitorsAnnals of the New York Academy of Sciences, 2013
- Genomic Determinants of PI3K Pathway Inhibitor Response in CancerFrontiers in Oncology, 2012
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Regulation of Proline-rich Akt Substrate of 40 kDa (PRAS40) Function by Mammalian Target of Rapamycin Complex 1 (mTORC1)-mediated PhosphorylationJournal of Biological Chemistry, 2008
- AKT crystal structure and AKT-specific inhibitorsOncogene, 2005
- Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifsNucleic Acids Research, 2003
- A Crucial Role for the p110δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and ActivationJournal of Experimental Medicine, 2002
- Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responsesBiochemical Journal, 1993